Forte Biosciences (FBRX) Misses Q4 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Citi Starts Forte Biosciences Inc. (FBRX) at Buy
March 26, 2021 5:20 AM EDTCiti analyst Mohit Bansal initiates coverage on Forte Biosciences Inc. (NASDAQ: FBRX) with a Buy rating and a price target of $75.00.
The analyst comments "We are initiating coverage of Forte (FBRX) with a Buy (High-Risk) as we think FB-401, the companys... More
